Evidence map›Paper›PMID 35893750›Full record

ArticleToxins2022

Individual Response to Botulinum Toxin Therapy in Movement Disorders: A Time Series Analysis Approach.

Bernd Leplow, Johannes Pohl, Julia Wöllner, David Weise

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Clinical efficacy of neuromodulation in isolated dystonia: A systematic review of motor function improvement.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bernd LeplowDepartment of Psychology, Martin Luther University Halle-Wittenberg, D-06120 Halle, Germany.
Johannes PohlDepartment of Psychology, Martin Luther University Halle-Wittenberg, D-06120 Halle, Germany.
Julia WöllnerMEU-Study Center of DIPLOMA University of Applied Science, D-39114 Magdeburg, Germany.ORCID 0000-0002-3009-9027
David WeiseDepartment of Neurology, Asklepios Fachklinikum Stadtroda, Bahnhofstr. 1a, D-07646 Stadtroda, Germany.
Martin Luther University Halle-Wittenberg · DEAsklepios Fachklinikum Brandenburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On a group level, satisfaction with botulinum neurotoxin (BoNT) treatment in neurological indications is high. However, it is well known that a relevant amount of patients may not respond as expected. The aim of this study is to evaluate the BoNT treatment outcome on an individual level using a statistical single-case analysis as an adjunct to traditional group statistics. The course of the daily perceived severity of symptoms across a BoNT cycle was analyzed in 20 cervical dystonia (CD) and 15 hemifacial spasm (HFS) patients. A parametric single-case autoregressive integrated moving average (ARIMA) time series analysis was used to detect individual responsiveness to BoNT treatment. Overall, both CD and HFS patients significantly responded to BoNT treatment with a gradual worsening of symptom intensities towards BoNT reinjection. However, only 8/20 CD patients (40%) and 5/15 HFS patients (33.3%) displayed the expected U-shaped curve of BoNT efficacy across a single treatment cycle. CD (but not HFS) patients who followed the expected outcome course had longer BoNT injection intervals, showed a better match to objective symptom assessments, and were characterized by a stronger certainty to control their somatic symptoms (i.e., internal medical locus of control). In addition to standard evaluation procedures, patients should be identified who do not follow the mean course-of-treatment effect. Thus, the ARIMA single-case time series analysis seems to be an appropriate addition to clinical treatment studies in order to detect individual courses of subjective symptom intensities.

Indexed as

Botulinum Toxins, Type AHemifacial SpasmMovement DisordersNeuromuscular AgentsTorticollisHumansTime FactorsBotulinum Toxins, Type ANeuromuscular AgentsadherenceARIMA single-case autoregressive integrated moving averagebotulinum neurotoxindystoniahemifacial spasm

Identifiers

PMID35893750
PMCPMC9332582
OpenAlexW4287219352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.